Mynvax

Mynvax is a clinical-stage biotechnology company focused on developing innovative, recombinant, and thermostable vaccines to protect against respiratory viral infections. The company operates in the biotechnology and pharmaceutical market, primarily serving low and lower-middle-income countries. Mynvax's business model revolves around research and development, leveraging collaborations with leading researchers and institutions, including the Indian Institute of Science (IISc), to create effective vaccine formulations. The company generates revenue through grant funding from Indian government agencies and commercial relationships with Contract Development and Manufacturing Organizations (CDMOs) and large vaccine manufacturers. Mynvax has demonstrated its vaccine design capabilities by quickly developing a thermotolerant COVID-19 vaccine formulation that is effective against various viral variants. The company's strategic partnerships and collaborations enhance its research, formulation expertise, and clinical development capabilities, ensuring the delivery of high-quality vaccines. Mynvax's commitment to science and technology aims to benefit humanity by providing accessible and effective vaccines.

Keywords: biotechnology, vaccines, respiratory infections, thermostable, COVID-19, low-income countries, IISc, collaborations, CDMOs, grant funding.